Institutional Ownership
Alnylam Pharmaceuticals Inc
CUSIP 02043Q107COMALNYQ1 2026
13D / 13G Filings
39
Schedule 13D/13G on record
Beneficial Filers
11
Distinct reporting persons
Largest Stake
15.0%
Max % of class reported
Institutional Holders
775
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
39 filings · latest Nov 5, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 5, 2025 | Fmr LLC | 13G/A | 12.8% | 16.83M | SEC |
| 2 | Apr 7, 2025 | The Vanguard Group | 13G/A | 10.0% | 13.06M | SEC |
| 3 | Feb 13, 2025 | Capital Research Global Investors | 13G | 5.4% | 6.97M | SEC |
| 4 | Nov 12, 2024 | Fmr LLC | 13G/A | 11.5% | — | SEC |
| 5 | Nov 8, 2024 | Wellington Management Group LLP | 13G/A | 3.9% | 5.02M | SEC |
| 6 | Aug 12, 2024 | Fmr LLC | 13G/A | 10.5% | — | SEC |
| 7 | Jul 5, 2024 | Baillie Gifford & Co | 13G/A | 4.8% | 6.03M | SEC |
| 8 | Feb 13, 2024 | Vanguard Group Inc | 13G/A | 9.5% | 11.94M | SEC |
| 9 | Feb 9, 2024 | Capital World Investors | 13G/A | 13.1% | 16.40M | SEC |
| 10 | Feb 9, 2024 | Wellington Management Group LLP | 13G/A | 5.8% | 7.25M | SEC |
29 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Alnylam Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 14.58M | $4.82B |
| 2 | Capital World Investors | 10.80M | $3.57B |
| 3 | Blackrock, Inc. | 10.44M | $3.46B |
| 4 | Capital Research Global Investors | 9.47M | $3.13B |
| 5 | Jpmorgan Chase & Co | 6.32M | $2.00B |
| 6 | State Street Corp | 3.32M | $1.10B |
| 7 | Geode Capital Management, LLC | 2.66M | $884.57M |
| 8 | Baillie Gifford & Co | 2.49M | $825.15M |
| 9 | Two Sigma Investments, LP | 1.99M | $659.28M |
| 10 | Wellington Management Group LLP | 1.94M | $640.54M |